^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Excerpt:
…partial or complete response and tumor regression (Table 2 and Fig. 2 and ​and3, and Table S3 and Fig. S2 and S3 in the Supplementary Appendix), and prolonged disease stabilization (Fig. S4 in the Supplementary Appendix) were observed in several tumor types, including non–small-cell lung cancer (8 partial responses in the cohort of 20 patients), Erdheim–Chester disease or Langerhans’-cell histiocytosis (1 complete and 5 partial responses in the cohort of 18 patients), anaplastic thyroid cancer (1 complete and 1 partial response in the cohort of 7 patients), cholangiocarcinoma (1 partial response in the cohort of 8 patients), with anecdotal responses in patients with salivary-duct cancer, clear-cell sarcoma, low-grade serous ovarian cancer, glioblastoma, anaplastic ependymoma, pancreatic cancer, and carcinoma of unknown primary type (supplimentary info).
DOI:
10.1056/NEJMoa1502309
Trial ID: